What Is Ascendis Pharma A/S (ASND) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Ascendis Pharma A/S's intrinsic value is estimated at $105.15. Trading at its current price of $265.22, the valuation engine raises significant caution: 10 of 12 models flag downside risk, projecting an average implied return of -60.4%. The most optimistic model, Markov DDM, places fair value at $506.68 (+91.0%), while Sentiment SOTP — the most conservative — estimates $2.76 (-99.0%). This +190.0% gap reflects genuine analytical uncertainty about Ascendis Pharma A/S's intrinsic worth.
What Do the Models Say About ASND?
12 of 13 models are currently active for ASND. Of these, 2 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates ASND's intrinsic value at $80.49, implying -69.7% downside from the current price. See which stocks rank higher →
How Does ASND Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, ASND ranks #121 by Quality of Company score. CirclFi's QOC score of 6.1/10 evaluates 32 fundamental signals. A score of 6.1 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Ascendis Pharma A/S's positioning within the Pharmaceutical Preparations segment means that patent cliff exposure plays an outsized role in fundamental analysis. The sector's unique characteristics — including regulatory pathway clarity — shape both the opportunity set and risk profile.
Is ASND a Value Trap?
CirclFi's Value Trap algorithm assigns ASND a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for Ascendis Pharma A/S. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, Ascendis Pharma A/S earns a quality score of 6.1/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.
The gap between the most bullish and bearish model spans +190.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ASND valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ASND's 12 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad